IP Library Granted Patent US 11,236,132
Granted Patent B2
US 11,236,132 · App. 16/662,278 · Granted Feb 1, 2022

Nepovirus coat protein fusion polypeptides and their use

Inventors: Lorène Belval (Colmar, FR); Gérard Demangeat (Ostheim, FR); Caroline Hemmer (Colmar, FR); Christophe Ritzenthaler (Selestat, FR)
Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT; UNIVERSITE DE STRASBOURG; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
C07K14/005C07K16/00C12N7/00C07K2317/569C07K2319/00C07K2319/60C12N2770/18022C12N2770/18023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,236,132
App. No.
16/662,278
Granted
Feb 1, 2022
Kind
B2
Abstract

The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.

Claims (11)

1. A virus-like particle comprising a nepovirus coat protein conjugated to a compound, wherein the compound is conjugated to the C-terminus of the coat protein by ligand-mediated attachment and the nepovirus coat protein is a grapevine fanleaf virus (GFLV) coat protein.

2. The particle of claim 1 , wherein the compound is conjugated to the coat protein by an anti-coat protein antibody or antibody derivative.

3. The particle of claim 2 , wherein the antibody derivative is a nanobody or an ScFv.

4. The particle of claim 2 , wherein the antibody derivative is a nanobody comprising a sequence selected from any one of SEQ ID NOs: 14-18 or a sequence having at least 90% sequence identity thereto.

5. The particle of claim 1 , wherein the coat protein is further conjugated in its N-terminus to a compound.

6. The particle of claim 5 , which comprises an encaged compound conjugated to the N-terminus of the coat protein, and an exposed compound, conjugated to the surface of the particle by antibody-mediated attachment.

7. The particle of claim 6 , wherein the exposed compound is a nanobody comprising a sequence selected from any one of SEQ ID NOs: 14-18 or a sequence having at least 90% sequence identity thereto.

8. The particle of claim 6 , said particle being nucleic acid-free.

9. The particle of claim 1 , wherein the coat protein comprises SEQ ID NO: 1, or a sequence having at least 90% identity to SEQ ID NO: 1.

10. The particle of claim 1 , wherein the compound is a therapeutic, diagnostic or imaging agent, or a tag.

11. A pharmaceutical composition comprising one or more virus-like particles of claim 1 .

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2021
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Reel/Frame 054972/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2019
From: RITZENTHALER, CHRISTOPHE
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 050816/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2019
From: DEMANGEAT, GERARD
To: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
Reel/Frame 050816/0880 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2019
From: BELVAL, LORÈNE; HEMMER, CAROLINE
To: UNIVERSITE DE STRASBOURG
Reel/Frame 050816/0956 →